Ablynx gains on RA data for vobarilizumab

Ablynx N.V. (Euronext:ABLX) gained EUR 1.42 (12%) to EUR 12.95 on Thursday after reporting 12-week data from a 251-patient Phase IIb study comparing three dosing regimens of vobarilizumab (ALX-0061) to more frequently dosed Actemra tocilizumab to treat moderately to severely active rheumatoid arthritis.

In the intent-to-treat population, the proportion of patients achieving an ACR20 response at week 12, the primary endpoint, was 73% and 77% for individuals who received 150 mg vobarilizumab every four or two weeks, respectively, and 81% for patients who received 225 mg vobarilizumab every two weeks. That compared to 78% for patients who received open-label Actemra, the majority of whom were dosed once weekly. ...